We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An interim report shows that the FDA has conducted nearly 90 meetings with more than 50 drug companies interested in producing biosimilar products since 2013 at a cost of $65.9 million. Read More
Bausch & Lomb and Nicox are calling their once-daily eye drop for treating both open angle glaucoma and ocular hypertension a milestone in research and development in a medical area that has seen few new treatments in recent years. Read More
Swiss health authority Swissmedic has approved Novartis’ Entresto, enabling other health authorities to complete their reviews of the heart failure drug. Read More
Allergan and partner Gedeon Richter received FDA approval Thursday for antipsychotic Vraylar to treat schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults. Read More
Addyi, the pill for premenopausal women with hypoactive sexual desire disorder, received FDA approval last month despite dissent from some reviewers that marginal clinical benefits did not outweigh the risks, an FDA summary said. Read More